Last reviewed · How we verify
Ascabin (BENZYL BENZOATE)
At a glance
| Generic name | BENZYL BENZOATE |
|---|---|
| Sponsor | Lannett |
| Drug class | benzyl benzoate |
| Target | Beta-lactamase, Hormone-sensitive lipase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1976 |
Approved indications
Common side effects
Key clinical trials
- Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015) (PHASE1)
- Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men (PHASE2)
- Dinalbuphine Ester (Naldebain) for Pain Management After Cesarean Section (PHASE2,PHASE3)
- The Effect of Oral Sprays on Salivary pH (PHASE4)
- The Effect of Pretreatment for Propionibacterium Acnes on Surgical Site Burden in Shoulder Arthroplasty (NA)
- Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma (PHASE2)
- Naldebain for Pain Management of Laparoscopic Cholecystectomy (PHASE2,PHASE3)
- Naldebain for Control of Post-Cesarean Section Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ascabin CI brief — competitive landscape report
- Ascabin updates RSS · CI watch RSS
- Lannett portfolio CI